name stringlengths 8 13 | light_chain_class stringclasses 2
values | type stringclasses 5
values | original_mab_isotype_or_format stringclasses 17
values | clinical_status stringclasses 3
values | phagec bool 2
classes | year_name_proposed int64 1.99k 2.01k | metadata_notes stringclasses 3
values | vh stringlengths 112 130 | vl stringlengths 104 113 | lc_class stringclasses 2
values | source stringclasses 3
values | source_detaileda stringlengths 4 9 | disclaimers_and_known_issues stringclasses 6
values | sequence_info_notes stringclasses 1
value | hek_titer_mg_l float64 6.58 277 | fab_tm_by_dsf_deg_c float64 59.5 91.5 | sgac_sins_as100_nh4_2so4_mm float64 0 1k | hic_retention_time_min_a float64 8.47 25 | smac_retention_time_min_a float64 8.49 25 | slope_for_accelerated_stability float64 -0.01 1.27 | poly_specificity_reagent_psr_smp_score_0_1 float64 0 0.81 | affinity_capture_self_interaction_nanoparticle_spectroscopy_ac_sins_delta_lambda_max_nm_average float64 -1.08 29.9 | cic_retention_time_min float64 8.26 13.5 | csi_bli_delta_response_nm float64 -0.05 0.6 | elisa float64 0.89 14.5 | bvp_elisa float64 1.03 22.7 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
pembrolizumab | kappa | ZU | IgG4-CPPC | Approved | false | 2,013 | null | QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK | kappa | WHO-INN | RL72 | null | null | 64.908983 | 66 | 500 | 11.073 | 13.477 | 0.0334 | 0.300425 | 5.622347 | 10.918 | 0.01 | 1.277062 | 2.234276 |
pertuzumab | kappa | ZU | IgG1 | Approved | false | 2,003 | null | EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK | kappa | PDB | 1S78 | null | null | 31.426915 | 78.5 | 700 | 10.112 | 8.913 | 0.03917 | 0 | -0.203825 | 8.597 | -0.04 | 1.213583 | 1.691847 |
pinatuzumab | kappa | ZU | IgG1-ADC | Phase 2 | false | 2,012 | null | EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGNTFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQGTKVEIK | kappa | WHO-INN | PL108 | null | null | 130.580857 | 79 | 800 | 9.224 | 8.827 | 0.06846 | 0.011366 | 0.589521 | 8.774 | -0.02 | 1.272171 | 2.485191 |
polatuzumab | kappa | ZU | IgG1 | Phase 2 | true | 2,012 | null | EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK | kappa | WHO-INN | PL108 | null | null | 225.055164 | 74 | 1,000 | 8.763 | 8.67 | 0.05931 | 0 | -1.003168 | 8.264 | -0.05 | 1.362537 | 3.622629 |
ponezumab | kappa | ZU | IgG2 | Phase 2 | true | 2,010 | null | QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS | DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK | kappa | WHO-INN | PL104 | null | null | 16.95786 | 61 | 800 | 10.499 | 9.004 | 0.1568 | 0.074359 | -0.239908 | 8.679 | -0.03 | 3.130063 | 6.623627 |
radretumab | kappa | HU | scFv-CH | Phase 2 | true | 2,010 | null | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK | kappa | WHO-INN | PL104 | null | null | 151.171797 | 77 | 900 | 9.514 | 8.69 | 0.001743 | 0.133677 | 3.384699 | 8.858 | 0 | 1.259504 | 3.286522 |
ramucirumab | kappa | HU | IgG1 | Approved | true | 2,008 | null | EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS | DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK | kappa | WHO-INN | PL100 | null | null | 90.668096 | 66 | 900 | 9.43 | 8.705 | 0.02434 | 0 | 0.015844 | 8.582 | -0.02 | 1.054893 | 1.249917 |
ranibizumab | kappa | ZU | Fab | Approved | true | 2,004 | null | EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK | kappa | PDB | 1CZ8 | null | null | 41.447866 | 65 | 300 | 12.142 | 18.059 | 0.0942 | 0 | 7.925273 | 10.058 | 0.02 | 1.607124 | 3.138103 |
reslizumab | kappa | ZU | IgG4 | Approved | false | 2,001 | null | EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK | kappa | US Patent | US5998586 | null | null | 191.568526 | 75.5 | 700 | 9.824 | 8.9 | 0.06217 | 0.23029 | 1.739301 | 8.864 | 0 | 1.251463 | 2.023295 |
rilotumumab | kappa | HU | IgG2 | Phase 3 | false | 2,009 | null | QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIK | kappa | WHO-INN | PL101 | null | null | 173.077795 | 79 | 500 | 12.633 | 17.684 | 1.2728 | 0.160022 | 2.12658 | 10.393 | 0 | 1.130871 | 2.373034 |
rituximab | kappa | XI | IgG1 | Approved | false | 1,997 | null | QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA | QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK | kappa | PDB | 2OSL | null | null | 164.141012 | 69 | 700 | 10.797 | 9.109 | 0.025 | 0.383866 | 2.133138 | 10.147 | -0.01 | 1.190297 | 2.929118 |
robatumumab | kappa | HU | IgG1 | Phase 2 | false | 2,008 | null | EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS | EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK | kappa | WHO-INN | PL100 | null | null | 117.115691 | 80 | 0 | 9.507 | 8.969 | 0.04534 | 0.266657 | 29.645095 | 9.752 | 0.14 | 5.219351 | 8.246256 |
romosozumab | kappa | ZU | IgG2 | Phase 3 | false | 2,011 | null | EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK | kappa | WHO-INN | PL106 | null | null | 227.687243 | 76 | 1,000 | 9.18 | 8.648 | 0.02831 | 0 | -1.019466 | 8.427 | -0.03 | 1.007345 | 1.46822 |
sarilumab | kappa | HU | IgG1 | Phase 3 | false | 2,011 | null | EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK | kappa | WHO-INN | PL106 | null | null | 181.786077 | 64 | 900 | 8.989 | 8.687 | 0.04986 | 0 | 1.113824 | 8.71 | -0.01 | 1.186912 | 2.168386 |
secukinumab | kappa | HU | IgG1 | Approved | false | 2,009 | null | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK | kappa | WHO-INN | PL102 | null | null | 148.958796 | 72 | 800 | 11.389 | 8.906 | 0.0492 | 0 | -0.584713 | 8.361 | -0.04 | 1.088862 | 1.694757 |
seribantumab | lambda | HU | IgG2 | Phase 2 | true | 2,012 | null | EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL | lambda | WHO-INN | PL108 | null | null | 189.98314 | 77.5 | 300 | 10.418 | 8.998 | 0.1544 | 0 | 21.208264 | 9.787 | 0.01 | 1.237431 | 2.97371 |
sifalimumab | kappa | HU | IgG1 | Phase 2 | false | 2,009 | null | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK | kappa | WHO-INN | PL101 | null | null | 158.632742 | 67 | 800 | 9.651 | 8.773 | 0.01314 | 0.06062 | 2.100484 | 9.02 | -0.02 | 2.595419 | 2.497171 |
siltuximab | kappa | XI | IgG1 | Approved | false | 2,008 | null | EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS | QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK | kappa | WHO-INN | PL100 | null | null | 95.667173 | 64.5 | 600 | 10.999 | 12.076 | 0.0133 | 0 | 2.637658 | 9.42 | -0.01 | 1.175326 | 1.549813 |
simtuzumab | kappa | ZU | IgG4-CPPC | Phase 2 | false | 2,012 | null | QVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS | DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK | kappa | WHO-INN | PL107 | null | null | 191.435366 | 66.5 | 800 | 10.407 | 9.571 | 0.1421 | 0.336875 | 0.880686 | 9.098 | 0 | 6.008056 | 10.411314 |
sirukumab | kappa | HU | IgG1 | Phase 3 | true | 2,011 | null | EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK | kappa | WHO-INN | PL105 | null | null | 109.806712 | 68 | 0 | 11.26 | 10.756 | 0.03969 | 0.359874 | 29.645095 | 10.79 | 0.08 | 2.174539 | 9.657903 |
tabalumab | kappa | HU | IgG4-CPPC | Phase 3 | false | 2,011 | null | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK | kappa | WHO-INN | PL105 | null | null | 121.595499 | 64 | 700 | 10.847 | 9.87 | 0.0618 | 0 | 1.955361 | 9.127 | -0.01 | 1.260386 | 3.681864 |
tanezumab | kappa | ZU | IgG2 | Phase 3 | true | 2,008 | null | QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK | kappa | PDB | 4EDW | null | null | 48.863766 | 75.5 | 700 | 12.386 | 10.689 | 0.0166 | 0.229612 | 2.171174 | 9.248 | -0.01 | 1.396358 | 4.827715 |
teplizumab | kappa | ZU | IgG1AA-mut | Phase 3 | false | 2,007 | null | QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSS | DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT | kappa | WHO-INN | PL97 | null | null | 150.875165 | 64.5 | 1,000 | 8.786 | 8.647 | 0.06126 | 0.311282 | 11.167121 | 9.365 | 0.02 | 1.673976 | 3.844925 |
tigatuzumab | kappa | ZU | IgG1 | Phase 2 | false | 2,007 | null | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK | kappa | WHO-INN | PL98 | null | null | 178.9678 | 64.5 | 700 | 10.02 | 8.732 | 0.0029 | 0.12877 | 5.489286 | 8.7 | -0.01 | 1.172939 | 1.702622 |
tildrakizumab | kappa | ZU | IgG1 | Phase 3 | false | 2,012 | null | QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK | kappa | WHO-INN | PL108 | null | null | 181.888073 | 77.5 | 600 | 11.079 | 9.868 | -0.005 | 0 | 0.814903 | 8.728 | -0.01 | 1.186253 | 1.769052 |
tocilizumab | kappa | ZU | IgG1 | Approved | false | 2,004 | null | QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK | kappa | US Patent | US5795965 | null | null | 139.649467 | 91.5 | 900 | 9.088 | 8.777 | 0.04516 | 0 | 1.318283 | 8.902 | 0 | 1.13555 | 2.807987 |
tovetumab | kappa | HU | IgG2 | Phase 2 | false | 2,013 | null | QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK | kappa | WHO-INN | PL109 | null | null | 277.180752 | 63.5 | 900 | 8.673 | 8.634 | 0.0131 | 0 | 2.245154 | 8.808 | -0.01 | 1.352145 | 2.951685 |
tralokinumab | lambda | HU | IgG4 | Phase 3 | true | 2,009 | null | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS | SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL | lambda | WHO-INN | PL102 | null | null | 121.427053 | 63 | 800 | 10.262 | 8.987 | 0.007743 | 0.157394 | 4.813687 | 8.8 | 0.09 | 1.286288 | 2.315474 |
trastuzumab | kappa | ZU | IgG1 | Approved | false | 1,997 | null | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | kappa | WHO-INN | PL103_ADC | Sequences taken from trastuzumab emtansine; identical to trastuzumab from other sources | null | 159.477627 | 78.5 | 800 | 9.657 | 8.752 | 0.04383 | 0 | 2.038127 | 8.843 | -0.02 | 1.063455 | 1.336439 |
tremelimumab | kappa | HU | IgG2 | Phase 3 | false | 2,005 | null | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK | kappa | US Patent | US6682736 | null | null | 229.592511 | 75 | 0 | 11.557 | 19.316 | 0.01757 | 0.145497 | 29.645095 | 11.242 | 0 | 1.211239 | 1.965391 |
urelumab | kappa | HU | IgG4 | Phase 2 | false | 2,010 | null | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK | kappa | WHO-INN | PL104 | VL sequence modified at one position to match patent document (US7659384) and JK germline | null | 143.923958 | 66 | 0 | 11.161 | 12.985 | 0.01389 | 0 | 29.645095 | 9.369 | 0.07 | 1.146375 | 1.531448 |
ustekinumab | kappa | HU | IgG1 | Approved | false | 2,008 | null | EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK | kappa | PDB | 3HMW | null | null | 152.722928 | 69.5 | 1,000 | 8.783 | 8.64 | 0.02254 | 0.153653 | 0.424236 | 8.633 | -0.01 | 2.184532 | 5.07421 |
vedolizumab | kappa | ZU | IgG1AA-mut | Approved | false | 2,008 | null | QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS | DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIK | kappa | WHO-INN | PL100 | null | null | 221.762037 | 80.5 | 600 | 10.942 | 12.307 | 0.06906 | 0 | 0.388178 | 8.986 | -0.02 | 1.152671 | 1.584027 |
veltuzumab | kappa | ZU | IgG1 | Phase 2 | false | 2,007 | null | QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS | DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK | kappa | WHO-INN | PL98 | null | null | 224.953517 | 70 | 700 | 11.092 | 9.725 | 0.0399 | 0 | 4.831871 | 8.792 | -0.02 | 0.888809 | 1.211236 |
visilizumab | kappa | ZU | IgG2 | Phase 3 | false | 2,000 | null | QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK | kappa | US Patent | US7381803 | null | null | 242.006377 | 71 | 0 | 9.007 | 8.695 | 0.0576 | 0.418071 | 21.988193 | 9.146 | 0.01 | 1.880772 | 4.799334 |
zalutumumab | kappa | HU | IgG1 | Phase 3 | false | 2,005 | null | QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK | kappa | US Patent | US8586041 | null | null | 200.50669 | 72.5 | 900 | 9.335 | 8.738 | 0.04983 | 0 | -0.79679 | 8.415 | -0.03 | 1.284363 | 2.896506 |
zanolimumab | kappa | HU | IgG1 | Phase 3 | false | 2,004 | null | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK | kappa | US Patent | US7722873 | null | null | 116.367688 | 80.5 | 700 | 9.586 | 8.768 | 0.02569 | 0.127128 | 1.457937 | 8.61 | -0.01 | 1.102262 | 1.455574 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.